Phathom Pharmaceuticals Inc
(NAS:PHAT)
$
13.84
1.03 (8.04%)
Market Cap: 945.13 Mil
Enterprise Value: 844.17 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 30/100 - Q4 2023 Phathom Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2024$9.09 (-6.58%)Earnings
- Phathom Pharmaceuticals Inc to Discuss The FDA Approval TranscriptNov 02, 2023
- Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Phathom Pharmaceuticals Inc Conference call on the PHALCON-EE Trial Results TranscriptOct 18, 2021
- Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- Phathom Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Phathom Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 21, 2021
- Phathom Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Phathom Pharmaceuticals Inc Phase 3 PHALCON-HP Results Corporate Call TranscriptApr 29, 2021
- Phathom Pharmaceuticals Inc Corporate Analyst Meeting TranscriptDec 14, 2020
- Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Phathom Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Phathom Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 21, 2020
Phathom Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021 / 02:00PM GMT
Release Date Price:
$35.91
(+1.58%)
David Steinberg
(Trades, Portfolio) LLC - Analyst
Good morning, everyone, and welcome to the Jefferies Healthcare Conference, day one. We are delighted to have with us the management team of Phathom. And with us today, as you can see, are Terrie Curran, CEO; Azmi Nabulsi, COO. Martin, where are you? There's Martin and he's Head of Sales and Marketing, and Todd Branning, Chief Financial Officer. So, welcome, everyone.
GI-focused Phathom is poised to introduce the next generation agent for managing GI-related disease with a compound called vonoprazan. The initial indications are for the treatment of erosive GERD and H. pylori. HP had very positive data last month, and the GERD data will read out in the coming months, and we have management with us today to get us caught up on progress.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)